Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of trastuzumab deruxtecan versus trastuzumab emtansine in high-risk HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy
MOH_2020-12-29_009608Phase 3Recruiting
- Sponsor
- Daiichi Sankyo, Inc
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing T-DXd arm with T-DM1 arm (2 arms). Primary endpoint: Invasive disease-free survival. Started Dec 2020; status: recruiting.
02
Drugs
trastuzumab deruxtecantrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-12-29_009608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-29_009608.